# Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

> **NCT02155634** · PHASE3 · WITHDRAWN · sponsor: **Celgene**

## Conditions studied

- Multiple Myeloma
- Neoplasms
- Plasma Cells
- Paraproteinemias
- Blood Protein Disorders
- Hematologic Diseases
- Therapeutic Uses

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02155634
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-07
- **Primary completion:** 2017-04
- **Final completion:** 2021-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was terminated due to poor feasibility and lack of interest at the participating sites.
- **Last updated:** 2018-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02155634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02155634, "Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02155634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*